In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells

Haematologica

Volumn 84, Issue 9, 1999, Pages 794-798

  Tosi, Patrizia ^a   Pellacani, Annalisa ^b   Zinzani, Pier Luigi ^b   Magagnoli, Massimo ^b   Visani, Giuseppe ^b   Tura, Sante ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

Apoptosis; CLL; Fludarabine; Gemcitabine

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; FLUDARABINE; GEMCITABINE; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKEMIA CELL; MALE; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; DEOXYCYTIDINE; DNA, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, BCL-2; HUMANS; LEUKEMIA, B-CELL, CHRONIC; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR STEM CELLS; VIDARABINE;

EID: 0032853279     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gale RP, Foon KA. Chronic lymphocytic leukemia: recent advances in biology and treatment. Ann Intern Med 1985; 103:101-20.
2. nd ed. New York:Churchill and Livingstone 1991, p. 7-14.
3. Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood 1987; 63:929-36.
4. Galton DAG, Wiltshaw E, Szur E, Dacie JV. The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukemia. Br J Hematol 1961; 7:73-98.
5. Liepman M, Votaw ML. The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 1978; 41:1664-9.
6. Oken MM, Kaplan ME. Combination chemotherapy with cyclophosphamide, vincristine and prednisone in the treatment of refractory chronic lymphocytic leukemia. Cancer Treat Rep 1979; 63:441-7.
7. Keating MJ, Kantarjian H, Talpaz M. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1988; 74:19-25.
8. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82:1695-700.
9. Zinzani PL, Lauria F, Rondelli D, et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur J Haematol 1993; 51:93-7.
10. Keating MJ, Kantarjian H, O'Brien S, et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9:44-9.
11. Spriano M, Clavio M, Carrara P, et al. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. Haematologica 1994; 79:218-26.
12. Bastion Y, Felman P, Dumontet C, Espinouse D, Coiffier B. Intensive radiochemotherapy with peripheral blood stem cell transplantation in young patients with chronic lymphocytic leukemia. Bone Marrow Transplant 1992; 10:467-8.
13. Khouri I, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12:748-58.
14. Hertel LW, Border JB, Kroin JS, et al. Evaluation of antitumor activity of gemcitabine (2′-2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50:4417-9.
15. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine:metabolism, mechanism of action and self-potentiation. Semin Oncol 1995; 22(Suppl 11):3-10.
16. Heinemann V, Schultz L, Issels RD, Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 1995;22 (Suppl 11):11-8
17. Heinemann V, Xu YZ, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′2′-difluorodeoxycytidine. Mol Pharmacol 1990; 38:567-72.
18. Santini V, Bernabei PA, Gozzini A, et al. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Haematologica 1997; 82:11-5.
19. Santini V, D'Ippolito G, Bernabei PA, Zoccolante A, Ermini A, Rossi-Ferrini P. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL-60. Direct comparison of cytotoxicity and cellular Ara-C uptake enhancement. Leuk Res 1996; 20:37-45.
20. Zinzani PL, Buzzi M, Farabegoli P, et al. Apoptosis induction with fludarabine on freshly isolated chronic myeloid leukemia cells. Haematologica 1994; 79: 127-31.
21. Zinzani PL, Tosi P, Visani G, et al. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994; 47:301-6.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs and enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
23. Tosi P, Visani G, Ottaviani E, Manfroi S, Zinzani PL, Tura S. Fludarabine-Ara-C+G-CSF: cytotoxic effects and induction of apoptosis on fresh acute leukemia cells. Leukemia 1994; 8:2076-82.
24. Tosi P, Pellacani A, Visani G, et al. In vitro treatment with retinoids decreases BCL-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells. Eur J Haematol 1998; 61:1-6.
25. Morabito F, Callea I, Console G, et al. The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia. Haematologica 1997; 82:560-5.
26. Mc Laughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 1996; 14:1262-8.
27. Yang LY, Li L, Keating MJ, et al. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol 1995; 47:1072-9.
28. Gandhi V, Novak B, Keating MJ, Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood 1989; 74:2070-5.
29. Postmus PE, Schranel FM, Smit EF, et al. Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine. Semin Oncol 1998; 25 (suppl 9):79-82.
30. Brand R, Capadano M,Tempero M. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and solid tumors. Invest New Drugs 1997; 15:331-41.
31. Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Annal Oncol 1998; 9:1351-3.
32. Santoro A, Devizzi L, Bonfante V, et al. Phase II study with gemcitabine in pretreated patients with Hodgkin's (HD) and non-Hodgkin's lymphomas (NHL): results of a multicentric study. Proc ASCO 1997; 16:A71.
33. Morabito F, Filangeri M, Callea I, et al. BCL-2 protein expression and p53 gene mutation in CLL: correlations with in vitro sensitivity to chlorambucil and purine analogs. Haematologica 1997; 82:16-20.
34. Iwasaki H, Huang P, Plunkett W. Differential incorporation of Ara-C, gemcitabine and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997; 90:270-8.